Astrazeneca India
- All
- News
- Videos
-
Failure of AstraZeneca Trial Big Blow For Anti-Addiction Drugs: Report
The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the challenges in developing non-opioid medications that treat addiction and withdrawal, according to a report.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Covishield Side Effects: Doctors' Group Urges Centre To Review All Covid Vaccines
In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
What Is TTS, A Rare Condition Caused By AstraZeneca's Covishield Vaccine
AstraZeneca, a British pharmaceutical giant, has admitted that its Covid-19 vaccine can result ina rare side effectknown as Thrombosis with Thrombocytopenia Syndrome (TTS).T
-
AstraZeneca Pharma's Cancer-Treating Drug Gets Regulator's Nod In India
AstraZeneca Pharma India Ltd on Wednesday said it has received an approval from the Drug Controller General of India (DCGI) for the cancer drug trastuzumab deruxtecan for treatment of metastatic breast cancer.
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
-
AstraZeneca India Gets Approval To Market Drug Treating Breast Cancer
Drug firm AstraZeneca India on Friday said it has received an approval from the Drugs Controller General of India to market its drug for the treatment of breast cancer.
-
AstraZeneca's Stock Rise 10%, A Day After Dividend Announcement Of Rs 8
AstraZeneca Pharma India Ltd.'s stock jumped nearly 10 per cent, a day after the company's board declared dividend of Rs 8 per share.
-
Failure of AstraZeneca Trial Big Blow For Anti-Addiction Drugs: Report
The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the challenges in developing non-opioid medications that treat addiction and withdrawal, according to a report.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Covishield Side Effects: Doctors' Group Urges Centre To Review All Covid Vaccines
In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its Covid vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the safety of the Covishield vaccine.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
Supreme Court Agrees To Hear Plea Over Covishield Side-Effect Concern
The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
No Side Effects From Our Vaccine: Covaxin Maker Amid AstraZeneca Row
The Covaxin was developed with a single-minded focus on safety first, said its maker Bharat Biotech on Thursday, days after British pharma giant AstraZeneca admitted that its Covid vaccine can cause rare side effects.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
What Is TTS, A Rare Condition Caused By AstraZeneca's Covishield Vaccine
AstraZeneca, a British pharmaceutical giant, has admitted that its Covid-19 vaccine can result ina rare side effectknown as Thrombosis with Thrombocytopenia Syndrome (TTS).T
-
AstraZeneca Pharma's Cancer-Treating Drug Gets Regulator's Nod In India
AstraZeneca Pharma India Ltd on Wednesday said it has received an approval from the Drug Controller General of India (DCGI) for the cancer drug trastuzumab deruxtecan for treatment of metastatic breast cancer.
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
-
AstraZeneca India Gets Approval To Market Drug Treating Breast Cancer
Drug firm AstraZeneca India on Friday said it has received an approval from the Drugs Controller General of India to market its drug for the treatment of breast cancer.
-
AstraZeneca's Stock Rise 10%, A Day After Dividend Announcement Of Rs 8
AstraZeneca Pharma India Ltd.'s stock jumped nearly 10 per cent, a day after the company's board declared dividend of Rs 8 per share.
